Alle Storys
Folgen
Keine Story von LifeWatch AG mehr verpassen.

LifeWatch AG

EANS-Adhoc: LifeWatch announces results for the third quarter 2010 as well as additional news (with document)

2 Dokumente

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
3-month report/LifeWatch Q3 2010 Results
03.11.2010
• LifeWatch reports loss for the third quarter 2010; revised outlook 
for 2010; • CEO Brent Cohen has left LifeWatch with immediate effect;
• CMS to introduce a nationally binding reimbursement rate of USD 738
for ACT services in the US taking effect from January 1, 2011; • 
Complete Media Release, Letter to Shareholders and presentation for 
the third quarter 2010 availabe at http://www.irlifewatch.com/
Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss 
Exchange: LIFE), the leading wireless remote cardiac and medical 
patient monitoring service provider in the U.S., today announces 
results for the third quarter 2010 and gives a revised outlook for 
2010. At the same time, LifeWatch is announcing that CEO Brent Cohen 
has left the company with immediate effect due to differences in 
opinion over the operational and strategic direction. Furthermore, 
health policy authority CMS yesterday announced the introduction of a
nationally binding reimbursement rate of USD 738 for ACT services. 
The new reimbursement rates will take effect from January 1, 2011.
Third Quarter 2010 Financial Highlights are as follows:
• Revenues of USD 19.5 million, a 42.6% decrease year-on-year
• LBIT and LBITDA of USD 2.9 million and USD 1.3 million, 
respectively
• Net loss of USD 3.2 million
• Positive operating cash flow of USD 0.3 million, the 10th quarter in a row
      of positive operating cash flows
• Cash, cash equivalents, marketable securities and structures of  USD  42.1
      million on September 30, 2010
• ACT enrollments of 18,184, a 9.8% decrease year-on-year
• NiteWatch Home Sleep Test enrollments of 546, a 12.4%  decrease  from  the
      prior quarter
• New and amended commercial contracts during the quarter: 28 ACT  contracts
      (14.2 million covered lives) and  12  NiteWatch  contracts  (24.8  million
      covered lives)
• Revising our 2010 outlook to USD 85 - 87 million of revenue, USD 7.5 - 8.5
      million of LBIT, 75,500  -  77,500  ACT  enrollments  and  1,900  -  2,100
      NiteWatch enrollments
The last twelve months have been marked by significant changes in the market
for remote cardiac monitoring services. While we have endeavored to adapt and
adjust to the new operating environment, certain issues are beyond 
our control and have adversely affected our business more than 
anticipated. Management is making every effort to mitigate the impact
of those industry and other operational challenges.
Management changes:
We have also to report the departure of Brent Cohen, who has decided 
to leave the company at short notice. For the immediate future, Yacov
Geva has agreed to act as interim CEO in addition to his 
responsibilities as Chairman.
National Reimbursement Rate of USD 738:
On November 2, 2010, the Centers for Medicare & Medicaid Services 
(CMS) set national pricing guidelines for payment code 93229, which 
is the CPT payment code used by Medicare for payment for our ACT 
service. The national pricing will go into effect on January 1, 2011 
and will establish a reimbursement rate of USD 738. While it is still
too early to fully appreciate the impact of this announcement, we 
believe this development will have a positive effect on our 
discussions with insurance carriers and strengthen our negotiating 
position on the Reimbursement Denial issue.
Reimbursement Denials:
The Reimbursement Denial issue in particular has had a significant 
impact on our recent financial results including sales and cost of 
goods sold. Unfortunately, the original estimate for the impact of 
lost business was not clearly understood when first discussed the 
issue during our Q1 2010 investor conference. With two full quarters 
of history under our belt of operating with Reimbursement Denials, it
became apparent that substantial more of our enrollments were 
affected than originally estimated. The company is appealing rejected
claims by insurance carriers and while the process is lengthy, we 
have already begun to see positive signs from our efforts.
Sales force:
The impact of Reimbursement Denials and the decrease in the number of
sales representatives have adversely affected enrollment growth and 
revenues. Sales training and marketing programs have been developed 
and implemented but the short term impact of these programs on 
revenues has been limited. We believe the current management change 
with the hiring of Stephen Zielinski as Senior Vice President of 
Sales and the initiatives currently underway will prove successful. 
Stephen Zielinksi is a veteran of the cardiology industry and has 
over 20 years of relevant experience including 13 years in senior 
sales positions at Boston Scientific in the Peripheral Vascular and 
Cardiology Divisions.
Service Enrollments:
Enrollments for our ACT service were down 9.8% to 18,184 during Q3 
2010 compared with 20,164 enrollments in Q3 2009. The decline in 
enrollments was primarily due to the impact of Reimbursement Denials.
NiteWatch enrollments declined 12.4% sequentially to 546 enrollments 
in Q3 2010 from 623 enrollments in the prior quarter. The launch of 
our NiteWatch service was poorly executed and resulted in enrollments
for the quarter below expectations. Total enrollments from ACT, 
NiteWatch, Event Monitor and Holter grew at a 1.3% rate to 59,027 
enrollments in Q3 2010 from 58,270 enrollments in Q3 2009.
NiteWatch Launch:
The ramp up of our NiteWatch service has not met our expectations 
with Q3 2010 enrollments below plan. While we continue to believe 
that the market is strategically important and attractive to the 
Company, our initial planning and execution are now being updated. 
The company signed 12 new commercial contracts covering 24.8 million 
lives during Q3 and a total of 53 new contracts covering 40 million 
lives year-to-date. This includes our signing in September of a 
national provider contract for NiteWatch with Aetna.
Operating Improvements:
In last quarter´s media release and presentation, we discussed 
various operational initiatives undertaken by LifeWatch to streamline
processes and activities with an estimated annual savings potential 
of USD 10 million. We are on track to reach our goals for most of the
efficiency initiatives, with a number of them such as cell phone 
activation/deactivation and reduction in personnel, already meeting 
annualized target savings. The company is aggressively reviewing all 
legacy processes with a view to conduct business more efficiently.
Revenues:
Revenues decreased 42.6% to USD 19.5 million in Q3 2010 from USD 34.1
million in Q3 2009. The decrease in revenues was primarily due to 
Reimbursement Denials, the overall reduction in reimbursement rates 
and an increase in the allowance for estimated price reductions and 
contractual adjustments.
Gross Profit:
Gross profit was USD 9.4 million in Q3 2010 with a margin of 48.0%, 
compared with USD 22.2 million with a 65.2% margin in Q3 2009. The 
decrease in gross margin is largely attributable to the decrease in 
average selling prices and the impact of Reimbursement Denials.
Operating Expenses:
The Company´s operating expenses for the third quarter of 2010 are 
broken down as follows:
• Research and Development (R&D) expenses were USD 1.3 million  or  6.9%  of
      total revenues, compared with USD 0.8 million or 2.3% of total revenues in
      Q3 2009
• Sales and Marketing (S&M) expenses were USD 5.0 million or 25.8% of  total
      revenues, compared with USD 6.2 million or 18.2% of total revenues  in  Q3
      2009
• General and Administration (G&A) expenses were USD 5.9 million or 29.9% of
      total revenues, compared with USD 6.5 million or 19.0% of  total  revenues
      in Q3 2009
Operating Profit:
LBIT was USD 2.9 million, compared with EBIT of USD 8.8 million with 
a margin of 25.8% in Q3 2009.  LBITDA reached USD 1.3 million, 
compared with EBITDA of USD 10.4 million with a margin of 30.6% in Q3
2009.
Net Income:
Net loss for the third quarter of 2010 was USD 3.2 million, compared 
with net income of USD 7.3 million recorded in Q3 2009. Fully-diluted
loss per share was USD 0.25 in the third quarter of 2010 compared 
with fully-diluted earnings per share of USD 0.55 reported for the 
third quarter of 2009.
Revised 2010 Outlook:
In response to the third quarter results and our expectations for the
near future, we have revised our outlook for 2010 to USD 85 - 87 
million of revenue, USD 7.5 - 8.5 million of LBIT, 75,500 - 77,500 
ACT enrollments and 1,900 - 2,100 NiteWatch enrollments.
About LifeWatch AG:
LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on 
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare 
technology and solution company, specializing in advanced telehealth 
systems and wireless remote patient monitoring services. LifeWatch 
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
has subsidiaries in the United States, the Netherlands, Japan, the 
United Kingdom, Switzerland and Israel. LifeWatch AG is the parent 
company of LifeWatch Services Inc., a leading US-based cardiac 
monitoring service provider, and manufacturer of telecardiology 
products. LifeWatch has also introduced a new program for Home Sleep 
Testing of Obstructive Sleep Apnea (OSA) patients under the brand 
name NiteWatch. For additional information, please visit 
www.lifewatch.com.
This press release includes forward-looking statements. All 
statements other than statements of historical facts contained in 
this press release, including statements regarding future results of 
operations and financial position, business strategy and plans and 
objectives for future operations, are forward- looking statements. 
The words "believe," "may," "will," "estimate," "continue," 
"anticipate," "intend," "expect" and similar expressions are intended
to identify forward-looking statements. LifeWatch AG has based these 
forward- looking statements largely on current expectations and 
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business 
strategy, short term and long term business operations and 
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking 
events and circumstances described may not occur and actual results 
could differ materially and adversely from those anticipated or 
implied in the forward- looking statements. All forward-looking 
statements are based only on data available to LifeWatch AG at the 
time of the issue of this press release. LifeWatch AG does not 
undertake any obligation to update any forward-looking statements 
contained in this press release as a result of new information, 
future events or otherwise.
THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF 
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR 
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES.  THIS 
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN 
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH 
OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES
OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER 
THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR 
DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT 
REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION 
REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS.  ANY PUBLIC 
OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE 
BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR 
ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED 
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL 
STATEMENTS OF THE ISSUER.
Attachments with Announcement:
http://resources.euroadhoc.com/us/qzo9kU3d
http://resources.euroadhoc.com/us/664ZRdr7
end of announcement                               euro adhoc

Further inquiry note:

For further information please contact:
Woo Kim, Senior Vice President of Strategy and Business Development, LifeWatch
Tel +1 847 813 4299 | Fax +1 847 813 24 48 | Email wkim@lifewatch.com

Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

Branche: Healthcare Providers
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market / XETRA
Berlin / free trade
SIX Swiss Exchange / Main Standard

Weitere Storys: LifeWatch AG
Weitere Storys: LifeWatch AG